Hantz Financial Services Inc. Purchases 15,620 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Hantz Financial Services Inc. boosted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 71.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 37,388 shares of the company’s stock after acquiring an additional 15,620 shares during the period. Hantz Financial Services Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,167,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Prospera Financial Services Inc grew its holdings in Teva Pharmaceutical Industries by 145.8% during the 4th quarter. Prospera Financial Services Inc now owns 163,246 shares of the company’s stock valued at $5,095,000 after buying an additional 96,845 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $461,000. EverSource Wealth Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares in the last quarter. Global Retirement Partners LLC grew its holdings in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares in the last quarter. Finally, Leonteq Securities AG purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $65,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $34.60 on Thursday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The stock has a 50 day moving average price of $32.15 and a two-hundred day moving average price of $31.23. The company has a market capitalization of $39.78 billion, a P/E ratio of 26.01, a PEG ratio of 3.35 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president directly owned 63,647 shares in the company, valued at $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the firm’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares of the company’s stock, valued at $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 934,459 shares of company stock valued at $31,122,931 over the last 90 days. 0.54% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TEVA. Scotiabank lifted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Piper Sandler reaffirmed an “overweight” rating and set a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Finally, JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.